Does selected immunological panel possess the value of predicting the prognosis of early-stage resectable non-small cell lung cancer?

Background The immune status in the tumor micro-environment of lung cancer is highly informative, and expression status of some biomarkers in the tumor micro-environment may have deep connected statistical characteristics which could indicate immune status and predict related clinical outcomes. In this study, a panel of 9 immune biomarkers are selected for their possible predictive value of clinical outcomes in early-stage resectable non-small cell lung cancer (NSCLC). Methods We introduced a new way of interpreting the expression of Immunohistochemistry-based biomarkers in predicting the prognosis of patients. Immunohistochemistry were performed on surgical samples from 139 patients with NSCLC. Cox regression and subgroup analysis were conducted for the screening of biomarkers that were significant in survival and prognosis. Afterwards, Principle Component Analysis was conducted on screened biomarkers in order to extract characteristic root, which were utilized by an Artificial Neuron Network (ANN) for the prediction of clinical outcomes. Results Six out of 9 biomarkers were considered significant and were selected for the data analysis. The KMO-Bartlett's Sphericity test was valid (0.658>0.5, P=0.0001). The principle component regression results indicated that the survival was associated with the principle component Z4 (Y=0.316×Z4+2.298, R=0.189, P=0.026). Also, regression-free survival was associated with the principle component Z4 and Z2 (Y=0.314×Z4+0.255×Z2+2.061, R=0.249, P=0.013). Principle components ranking (PCrank) was calculated and after the determination of a cutoff of 0.2, the intergroup comparison of subgrouphigh (PCrank value above 0.2) and subgrouplow (PCrank value below 0.2) was significant in overall survival (OS) (P=0.025). A database search validated our results. Afterwards, the ANN model successfully predicted the clinical outcome, with accuracies of 94.1% and 96.2% respectively in models 1 and 2. Conclusions The selected immunological panels have promising potential for predicting the prognosis of resectable NSCLC.

[1]  J. Pignon,et al.  Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients. , 2019, European journal of cancer.

[2]  Shogo Kobayashi,et al.  Various checkpoint molecules, and tumor-infiltrating lymphocytes in common pediatric solid tumors: Possibilities for novel immunotherapy , 2019, Pediatric hematology and oncology.

[3]  G. Zhu,et al.  Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3 , 2019, Cell.

[4]  J. Soria,et al.  Hyperprogressive disease: recognizing a novel pattern to improve patient management , 2018, Nature Reviews Clinical Oncology.

[5]  B. Nelson,et al.  Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study , 2018, Oncoimmunology.

[6]  A. Mansfield,et al.  First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[7]  Jiaqian Wang,et al.  MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design , 2018, BMC Genomics.

[8]  A. Lánczky,et al.  Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets , 2018, Scientific Reports.

[9]  C. Romagnani,et al.  Boosting Type 2 Immunity: When OX40L Comes from ILC2s. , 2018, Immunity.

[10]  B. J. Morrison,et al.  Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells , 2018, BMC cancer.

[11]  P. Kelly,et al.  The Cancer Immunotherapy Revolution. , 2018, Science.

[12]  E. Felip,et al.  Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer , 2018, JAMA oncology.

[13]  S. Nomura,et al.  Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab , 2018, International Journal of Clinical Oncology.

[14]  T. Jiang,et al.  Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis , 2018, Cancer Immunology, Immunotherapy.

[15]  Inge M. N. Wortel,et al.  Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment , 2018, The Journal of Immunology.

[16]  S. Leung,et al.  LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Diehn,et al.  Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non–Small Cell Lung Cancer , 2017, JAMA oncology.

[18]  F. Hirsch,et al.  MHC class II expression in lung cancer. , 2017, Lung cancer.

[19]  L. Varani,et al.  The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells , 2017, EBioMedicine.

[20]  E. Tartour,et al.  Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer , 2017, ESMO Open.

[21]  F. Hirsch,et al.  LAG‐3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD‐1/PD‐L1 and Tumor‐Infiltrating Lymphocytes , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  F. Hirsch,et al.  PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes , 2017, Medical science monitor : international medical journal of experimental and clinical research.

[23]  W. Dempke,et al.  Second- and third-generation drugs for immuno-oncology treatment-The more the better? , 2017, European journal of cancer.

[24]  Walter J Curran,et al.  Lung cancer: current therapies and new targeted treatments , 2017, The Lancet.

[25]  P. Bunn,et al.  KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer , 2016, Oncotarget.

[26]  Zhenjie Wu,et al.  Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma , 2016, World Journal of Urology.

[27]  Shohei Koyama,et al.  Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.

[28]  Yanghua Qin,et al.  Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients. , 2015, American journal of cancer research.

[29]  Aurélien Marabelle,et al.  Immune Checkpoint Modulation for Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[30]  D. Fearon,et al.  T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.

[31]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Tamada,et al.  Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma , 2013, The Journal of Immunology.

[33]  M. Smyth,et al.  Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. , 2011, Cancer research.

[34]  F. Aoudjit,et al.  MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis , 2011, The Journal of Immunology.

[35]  Jenna M. Sullivan,et al.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.

[36]  Lloyd J. Old,et al.  Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer , 2010, Proceedings of the National Academy of Sciences.

[37]  Steven C Almo,et al.  T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. , 2007, Immunity.

[38]  A. Weinberg,et al.  Anti‐OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses , 2007, European journal of immunology.

[39]  D. Vignali,et al.  Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-31 , 2002, The Journal of Immunology.

[40]  Tatyana Chernova,et al.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease , 2002, Nature.

[41]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[42]  P. Hegde,et al.  Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[43]  J. Machiels,et al.  Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival , 2018, Journal of the National Cancer Institute.